- Home
- HAIN vs CRDF Comparison
HAIN vs CRDF Comparison
Compare HAIN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAIN
- CRDF
- Stock Information
- Founded
- HAIN 1993
- CRDF 1999
- Country
- HAIN United States
- CRDF United States
- Employees
- HAIN N/A
- CRDF N/A
- Industry
- HAIN Packaged Foods
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAIN Consumer Staples
- CRDF Health Care
- Exchange
- HAIN Nasdaq
- CRDF Nasdaq
- Market Cap
- HAIN 146.2M
- CRDF 210.2M
- IPO Year
- HAIN 1993
- CRDF N/A
- Fundamental
- Price
- HAIN $1.66
- CRDF $3.51
- Analyst Decision
- HAIN Hold
- CRDF Strong Buy
- Analyst Count
- HAIN 9
- CRDF 5
- Target Price
- HAIN $3.91
- CRDF $10.50
- AVG Volume (30 Days)
- HAIN 1.5M
- CRDF 1.4M
- Earning Date
- HAIN 05-07-2025
- CRDF 08-07-2025
- Dividend Yield
- HAIN N/A
- CRDF N/A
- EPS Growth
- HAIN N/A
- CRDF N/A
- EPS
- HAIN N/A
- CRDF N/A
- Revenue
- HAIN $1,615,231,000.00
- CRDF $587,000.00
- Revenue This Year
- HAIN N/A
- CRDF N/A
- Revenue Next Year
- HAIN N/A
- CRDF N/A
- P/E Ratio
- HAIN N/A
- CRDF N/A
- Revenue Growth
- HAIN N/A
- CRDF N/A
- 52 Week Low
- HAIN $1.30
- CRDF $2.01
- 52 Week High
- HAIN $9.43
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- HAIN 44.46
- CRDF 55.21
- Support Level
- HAIN $1.46
- CRDF $2.96
- Resistance Level
- HAIN $1.77
- CRDF $3.24
- Average True Range (ATR)
- HAIN 0.12
- CRDF 0.26
- MACD
- HAIN 0.02
- CRDF -0.05
- Stochastic Oscillator
- HAIN 45.45
- CRDF 38.73
About HAIN Hain Celestial Group Inc. (The)
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.